Effects of cell cycle dependent kinases inhibitor on nuclear and cytoplasmic maturation of porcine oocytes.
The aims of this study were to assess the effectiveness of roscovitine, a potent inhibitor of cell cyclin kinases, to prevent meiotic resumption in porcine oocytes, and to test the subsequent fertilisability and developmental competence of these oocytes. Roscovitine blocked porcine oocytes at the GV stage during 22-44 hr of culture. This effect was dose-dependent, and a concentration of 25 microM was sufficient to prevent meiotic resumption in 92+/-5% of the oocytes after 22 hr in the presence of EGF and FSH. Cumulus expansion was also inhibited under these conditions. The histone H1 kinase activity in oocytes was inhibited in a dose-dependent way, and maintained at a basal level with 25 microM of roscovitine. Synthesis of proteins of 29, 47 and 79 kDa, normally synthesized during maturation, was inhibited too. All these effects were fully reversible. However, the kinetics of maturation were accelerated after roscovitine removal, and the acceleration was more pronounced after 44 hr of inhibition than after 22 hr. Fertilization of oocytes blocked for 22 hr before a 44 hr maturation was decreased compared to control, but was not different from that of oocytes matured for 66 hr. The developmental competence was decreased for the oocytes cultured for 66 hr, including or not an inhibition period, but it was less reduced for oocytes maintained under inhibition for 22 hr. Roscovitine may thus protect oocytes against the aging mechanisms responsible for developmental competence loss, but not against loss of fertilisability. In conclusion, roscovitine provides a useful tool to study the morphological and biochemical basis of porcine oocyte terminal differentiation.
Marchal
R
R
INRA, Station de Physiologie de la Reproduction et des Comportements, Nouzilly, France.
Tomanek
M
M
Terqui
M
M
Mermillod
P
P
D000818:Animals; D002453:Cell Cycle / Q000187:drug effects; D002467:Cell Nucleus / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D003593:Cytoplasm / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D008540:Meiosis / Q000187:drug effects; D009865:Oocytes / Q000166:cytology* / Q000187:drug effects* / Q000254:growth & development; D014176:Protein Biosynthesis; D011494:Protein Kinases / Q000378:metabolism; D011687:Purines / Q000494:pharmacology*; D000077546:Roscovitine; D013552:Swine / Q000378:metabolism; D013997:Time Factors
D011687:Purines; D000077546:Roscovitine; D011494:Protein Kinases; C102333:histone H1 kinase; D018844:Cyclin-Dependent Kinases